^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    S100A8 elevation

    i
    Other names: S100A8, S100 Calcium Binding Protein A8, Migration Inhibitory Factor-Related Protein 8, Leukocyte L1 Complex Light Chain, Urinary Stone Protein Band A, Calprotectin L1L Subunit, Cystic Fibrosis Antigen, Protein S100-A8, Calgranulin A, CAGA, CFAG, MRP8, S100 Calcium-Binding Protein A8 (Calgranulin A), S100 Calcium-Binding Protein A8, Calgranulin-A, 60B8AG, CP-10, MA387, MRP-8, CGLA, L1Ag, MIF, NIF
    Entrez ID:
    6279
    Related biomarkers:
    Expression
    Others
    10ms
    S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma. (PubMed, Front Oncol)
    Inhibition of S100A8 could promote cell apoptosis and suppress tumor growth. Meanwhile, S100A8 has the potential to be a promising immunotherapeutic target for patients with DLBCL.
    Journal • IO biomarker
    |
    S100A8 (S100 Calcium Binding Protein A8) • IL17A (Interleukin 17A)
    |
    S100A8 elevation • S100A8 expression
    1year
    S100A8/A9 as a risk factor for breast cancer negatively regulated by DACH1. (PubMed, Biomark Res)
    S100A8/A9 is remarkedly increased in basal-like and Her2-overexpressed subtypes, predicting poor prognosis of breast cancer patients. Tumor suppressor DACH1 inhibits S100A8/A9 expression. The combination of S100A8/A9 and DACH1 predicted the overall survival of breast cancer patients more preciously.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9) • DACH1 (Dachshund Family Transcription Factor 1)
    |
    HER-2 positive • HER-2 overexpression • S100A8 elevation • S100A8 expression